1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,440 | 4,650 | 12:14 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux | 175 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 07.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 223 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 02.07. | MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg in acute Graft-versus Host Disease in Europe | 393 | Business Wire | MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg(MaaT013), its first in class treatment proposed for patients... ► Artikel lesen | |
| 24.06. | MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting | 270 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies(MET) dedicated to enhancing... ► Artikel lesen | |
| 19.06. | MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 | 339 | Business Wire | Marketing Authorization application of Xervyteg (MaaT013) in acute graft-versus-host-disease submitted to the European Medicines Agency (EMA) in June 2025
MAA could be expected in H2 2026... ► Artikel lesen | |
| 13.06. | MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease | 341 | Business Wire | Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg
Independent dataset from EAP reinforces... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 02.06. | MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg (MaaT013) in Acute Graft-versus-Host Disease | 405 | Business Wire | MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg
Xervyteghas... ► Artikel lesen | |
| 14.05. | MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress | 311 | Business Wire | Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
Poster presentation selected... ► Artikel lesen | |
| 14.05. | MaaT Pharma to Hold Annual General Meeting on June 20, 2025 | 336 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 13.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 | 318 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 12.05. | MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 321 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 29.04. | AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology | - | pharmaphorum | ||
| 28.04. | MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 | 301 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 14.04. | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | 253 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 08.04. | MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 329 | Business Wire | Following a milestone unblinded interim safety review, the independent Data Safety Monitoring Board (DSMB) has recommended that the study proceed without modification. MaaT033, a pooled... ► Artikel lesen | |
| 07.04. | MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co | 442 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 04.04. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 376 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 31.03. | MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies | 366 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 27.03. | MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results | 853 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year... ► Artikel lesen | |
| 19.03. | MaaT Pharma stock adds 7% on DSMB nod | 3 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,234 | -0,49 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen | |
| HEIDELBERG PHARMA | 4,140 | -3,72 % | EQS-DD: Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Bezug von 90.000 Aktien aufgrund der Ausübung von 90.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2011 (Tranche 2; Ausgabe 2016) ... | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
24.07.2025 / 14:23... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,705 | +1,12 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,263 | -3,34 % | PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications | ||
| CENTOGENE | 0,130 | +22,64 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 2,980 | -2,10 % | Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset | ||
| BIOMERIEUX | 124,20 | -1,27 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| CYCLACEL | 13,772 | +2,01 % | Cyclacel Pharmaceuticals, Inc. - S-4, Registration of securities, business combinations | ||
| CYBIN | 6,850 | +0,74 % | Cybin Inc.: Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder | - EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will... ► Artikel lesen | |
| ADICET BIO | 0,647 | 0,00 % | Adicet Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| EQUILLIUM | 0,309 | -9,38 % | Equillium, Inc. - 8-K, Current Report | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 28,000 | +2,19 % | Genus: Underlying Group Trading In-line With Expectations | LONDON (dpa-AFX) - Genus (GNS.L) issued trading update for fiscal year ended 30 June 2025. The Group said it recorded strong underlying Group trading in-line with expectations. As a result of... ► Artikel lesen | |
| ANAPTYSBIO | 23,200 | +0,87 % | Analyst Expectations For AnaptysBio's Future | ||
| XTL BIOPHARMACEUTICALS | 1,390 | -3,47 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer |
MAAT PHARMA SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,92 % bei einem Aktienkurs von 4,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.